Clinical trials: Conjunctivitis
Persistent Corneal Epithelial Defect
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants…
- Trial name
- NCT07519902
- Testing
- Cenegermin, Vehicle
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Allergic Rhinoconjunctivitis
Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure
The goal of this pilot study is to develop an eye allergen challenge model, called a conjunctival allergen challenge (CAC), using timothy grass as the allergen.
- Trial name
- INQUIRE (NCT07801625)
- Testing
- Standardized Allergen Extract, Timothy Grass (Phleum pratense)
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dr. Anne Ellis
Ocular Inflammation, Keratoconjunctivitis
Tolerability Comparison of Flarex to Lotemax SM
This study compared the ocular tolerability of fluorometholone acetate ophthalmic suspension 0.1% (FLAREX) to loteprednol etabonate ophthalmic gel 0.38% (Lotemax SM) in adult subjects.
- Conditions
- Ocular Inflammation, Keratoconjunctivitis, Dry Eye Disease (DED), Post-operative Complications
- Trial name
- NCT07588074
- Testing
- Fluorometholone Acetate Ophthalmic Suspension 0.1%, Loteprednol Etabonate Ophthalmic Gel 0.38%
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Harrow Inc
Acute Infectious Keratoconjunctivitis
Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK).
- Trial name
- NCT05636228
- Testing
- INV-102, Vehicle
- Where
- 12 sites in United States, Thailand
- Volunteers
- 93 people
- Sponsor
- Invirsa, Inc.
Allergic Conjunctivitis of Both Eyes
Daydrop® Triple Action for Allergic Eye Symptoms
The study is designed to evaluate the safety and efficacy of Daydrop® Triple Action for the symptomatic treatment of seasonal or perennial allergic conjunctivitis.
- Trial name
- NCT07805759
- Testing
- Eye Drops, Lubricant
- Where
- Spain
- Volunteers
- 49 people
- Sponsor
- i+Med S.Coop.
Allergic Conjunctivitis
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
This study is researching 2 experimental drugs, REGN5713 and REGN5715. The study drugs will be either of these drugs given alone (either REGN5713 or REGN5715) or given together (REGN5713 and REGN5715) to reduce eye allergy signs…
- Trial name
- NCT07309432
- Testing
- REGN5713, REGN5715
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Conjunctivitis
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy
This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat".
- Trial name
- NCT07675811
- Testing
- REGN-2Cat, Freneslerbart, Mevonlerbart
- Where
- United States
- Volunteers
- 570 people
- Sponsor
- Regeneron Pharmaceuticals
Ocular Surface Allergy, Conjunctivitis, Allergic
Treatment of Ocular Surface Inflammations
The goal of this clinical trial is to learn if topical Cyclosporine 1% works to treat severe allergic ocular surface inflammation in pediatric population.
- Conditions
- Ocular Surface Allergy, Conjunctivitis, Allergic, Blepharoconjunctivitis
- Trial name
- NCT07732855
- Testing
- Topical Cyclosporine 1%
- Where
- Hungary
- Volunteers
- 50 people
- Sponsor
- Semmelweis University
Conjunctivitis Allergic
A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch Allergy
The purpose of this Patient Identification and Characterization (PIC) study is to collect information and perform limited allergy-related procedures to determine if participants can qualify for cat and/or birch tree pollen…
- Trial name
- NCT07710846
- Testing
- Noninterventional
- Volunteers
- 1,500 people
- Sponsor
- Regeneron Pharmaceuticals
Bacterial Conjunctivitis
Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis
This is a seamless Phase I/II, randomized, double-masked, placebo-controlled, multicenter trial to evaluate single and multiple-dose safety and tolerability of SUM-191 in healthy participants in Parts 1 (SAD) and 2 (MAD) ; and…
- Trial name
- NCT07565103
- Testing
- SUM-191
- Where
- United States
- Volunteers
- 426 people, healthy volunteers welcome
- Sponsor
- Senju USA, Inc.
Artifical Intelligence, Cataract
Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye
This is a multi-center, cross-sectional study evaluating a smartphone-based artificial intelligence (AI) system for anterior segment eye disease screening.
- Conditions
- Artifical Intelligence, Cataract, Pterygium, Keratopathy
- Trial name
- LENS (NCT07634913)
- Testing
- Smartphone-based on-device artificial intelligence system for anterior segment eye disease screening
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Allergic Conjunctivitis
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in…
- Trial name
- NCT05234554
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy
This study is researching 2 experimental drugs, REGN1908 and REGN1909, which are called REGN1908-1909 when mixed together (called "study drug") to reduce eye allergy signs and symptoms from cat allergy.
- Trial name
- NCT06602726
- Testing
- REGN1908, REGN1909
- Where
- 4 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Ophthalmological Adverse Events of Tralokinumab in AD
Atopic dermatitis (AD) is a skin disease characterised by xerosis, pruritus and erythematous plaques. It is common in children (10 to 20%) with an increasing prevalence (multiplied by 2 in 20 years) and begins to develop at 3…
- Trial name
- TRALO-Oeil (NCT05682976)
- Where
- 11 sites in France
- Volunteers
- 100 people
- Sponsor
- Nantes University Hospital
Vernal Keratoconjunctivitis
3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis
The aim of the study is to investigate whether patients with moderate-to-severe VKC and keratitis will benefit from the addition of Diquafosol ophthalmic solution in terms of symptoms and signs of VKC, tear film metrics, ocular…
- Trial name
- NCT06903884
- Testing
- 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion, 0.1% Cyclosporin A cationic ophthalmic emulsion
- Where
- Hong Kong
- Volunteers
- 94 people
- Sponsor
- The University of Hong Kong
Dry Eye Syndrome, Infectious Keratoconjunctivitis
Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface
This study aims to obtain the lacrimal fingerprint for frequent pathologies of the ocular surface and establish a normative base for each of them.
- Conditions
- Dry Eye Syndrome, Infectious Keratoconjunctivitis, Mucous Membrane Pemphigoid, Allergic Conjunctivitis
- Trial name
- EML-MSO (NCT04198740)
- Testing
- Tear sample collection via Schirmer strip and subsequent analysis by mass spectrometry
- Where
- 2 sites in Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Moderate to Severe Vernal Keratoconjunctivitis
A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
The aim of the study is to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants with Moderate to Severe Vernal Keratoconjunctivitis
- Trial name
- NCT07169695
- Testing
- Slit Lamp Examination, Far Best Corrected Visual Acuity (BCVA), T1695
- Where
- 11 sites in India
- Volunteers
- 120 people
- Sponsor
- Laboratoires Thea
Allergic Conjunctivitis
A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy
This study is researching 2 experimental drugs, REGN5713 and REGN5715, which are called REGN5713-5715 when mixed together (called "study drug") to reduce eye allergy signs and symptoms due to birch tree pollen allergy.
- Trial name
- NCT06602739
- Testing
- REGN5713, REGN5715
- Where
- 3 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Infectious Conjunctivitis (Disorder)
The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis
The objective of this study is to evaluate the efficacy of Sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.
- Trial name
- SCH1TAIC (NCT05356793)
- Testing
- SCH-1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Sacsh
Bacterial Conjunctivitis
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1%…
- Trial name
- NCT06911424
- Testing
- Fusidic Acid 1%
- Where
- 38 sites in United States
- Volunteers
- 400 people
- Sponsor
- Baxis Pharmaceuticals, Inc.